Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04271475 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
A Phase 3 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 3
- Development phase
- 127
- Enrollment target
NCT04271475 is a Phase 3 study that was terminated before completion, run by Actelion. The registered enrollment target is 127 participants.
The verdict
NCT04271475, a Phase 3 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
Interventions
- DRUG Placebo
- DRUG Macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04271475
The ClinicalTrials.gov registry entry for NCT04271475 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04271475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04271475 about?
NCT04271475 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension". The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
What is the current status of trial NCT04271475?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 127 participants. The study started on 2020-07-07. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT04271475?
The interventions under investigation include: Placebo (DRUG), Macitentan (DRUG).
Who is sponsoring clinical trial NCT04271475?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.